121 related articles for article (PubMed ID: 9463571)
1. Immunohistochemical expression of cathepsin D in correlation with extracellular matrix component, steroid receptor status and proliferative indices in breast cancer.
Ioachim E; Kamina S; Kontostolis M; Agnantis NJ
Virchows Arch; 1997 Nov; 431(5):311-6. PubMed ID: 9463571
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase expression in human breast cancer: an immunohistochemical study including correlation with cathepsin D, type IV collagen, laminin, fibronectin, EGFR, c-erbB-2 oncoprotein, p53, steroid receptors status and proliferative indices.
Ioachim EE; Athanassiadou SE; Kamina S; Carassavoglou K; Agnantis NJ
Anticancer Res; 1998; 18(3A):1665-70. PubMed ID: 9673387
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical evaluation of cathepsin D expression in colorectal tumours: a correlation with extracellular matrix components, p53, pRb, bcl-2, c-erbB-2, EGFR and proliferation indices.
Ioachim EE; Goussia AC; Machera M; Tsianos EV; Kappas AM; Agnantis NJ
Anticancer Res; 1999; 19(3A):2147-55. PubMed ID: 10470163
[TBL] [Abstract][Full Text] [Related]
5. Thymidine phoshorylase expression in breast cancer: the prognostic significance and its association with other angiogenesis related proteins and extracellular matrix components.
Ioachim E
Histol Histopathol; 2008 Feb; 23(2):187-96. PubMed ID: 17999375
[TBL] [Abstract][Full Text] [Related]
6. Expression of cathepsin D in urothelial carcinoma of the urinary bladder: an immunohistochemical study including correlations with extracellular matrix components, CD44, p53, Rb, c-erbB-2 and the proliferation indices.
Ioachim E; Charchanti A; Stavropoulos N; Athanassiou E; Bafa M; Agnantis NJ
Anticancer Res; 2002; 22(6A):3383-8. PubMed ID: 12530091
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression.
Ioachim E; Charchanti A; Briasoulis E; Karavasilis V; Tsanou H; Arvanitis DL; Agnantis NJ; Pavlidis N
Eur J Cancer; 2002 Dec; 38(18):2362-70. PubMed ID: 12460779
[TBL] [Abstract][Full Text] [Related]
8. Expression and Circulating Levels of Perlecan in Breast Cancer - Implications for Oestrogen Dependent Stromal Remodeling.
Jansson M; Billing O; Herdenberg C; Lundin C; Tolockiene E; Nazemroaya A; Sund M
J Mammary Gland Biol Neoplasia; 2020 Mar; 25(1):69-77. PubMed ID: 32124140
[TBL] [Abstract][Full Text] [Related]
9. Proliferation marker MIB-1 correlates well with proliferative activity evaluated by BrdU in breast cancer: an immunohistochemical study including correlation with PCNA, p53, c-erbB-2 and estrogen receptor status.
Moriki T; Takahashi T; Kataoka H; Hiroi M; Yamane T; Hara H
Pathol Int; 1996 Dec; 46(12):953-61. PubMed ID: 9110347
[TBL] [Abstract][Full Text] [Related]
10. Multicentric mammary carcinoma: evidence of monoclonal proliferation.
Middleton LP; Vlastos G; Mirza NQ; Eva S; Sahin AA
Cancer; 2002 Apr; 94(7):1910-6. PubMed ID: 11932891
[TBL] [Abstract][Full Text] [Related]
11. Dissociated overexpression of cathepsin D and estrogen receptor alpha in preinvasive mammary tumors.
Roger P; Daures JP; Maudelonde T; Pignodel C; Gleizes M; Chapelle J; Marty-Double C; Baldet P; Mares P; Laffargue F; Rochefort H
Hum Pathol; 2000 May; 31(5):593-600. PubMed ID: 10836299
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical visualisation of cathepsin-D expression in breast cancer.
Barthell E; Mylonas I; Shabani N; Kunze S; Kuhn C; Jeschke U; Friese K
Anticancer Res; 2007; 27(4A):2035-9. PubMed ID: 17649818
[TBL] [Abstract][Full Text] [Related]
13. Ki-67 is a prognostic marker for hormone receptor positive tumors.
Pérez-López ME; García-Gómez J; Alves MT; Paradela A; García-Mata J; García-Caballero T
Clin Transl Oncol; 2016 Oct; 18(10):996-1002. PubMed ID: 26742937
[TBL] [Abstract][Full Text] [Related]
14. Expression of nuclear insulin receptor substrate 1 in breast cancer.
Sisci D; Morelli C; Garofalo C; Romeo F; Morabito L; Casaburi F; Middea E; Cascio S; Brunelli E; Andò S; Surmacz E
J Clin Pathol; 2007 Jun; 60(6):633-41. PubMed ID: 16882697
[TBL] [Abstract][Full Text] [Related]
15. Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation.
Nakopoulou L; Stefanaki K; Panayotopoulou E; Giannopoulou I; Athanassiadou P; Gakiopoulou-Givalou H; Louvrou A
Hum Pathol; 2002 Sep; 33(9):863-70. PubMed ID: 12378509
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
17. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value.
Spyratos F; Ferrero-Poüs M; Trassard M; Hacène K; Phillips E; Tubiana-Hulin M; Le Doussal V
Cancer; 2002 Apr; 94(8):2151-9. PubMed ID: 12001111
[TBL] [Abstract][Full Text] [Related]
18. Association between histology grade, expression of HsMCM2, and cyclin A in human invasive breast carcinomas.
Bukholm IR; Bukholm G; Holm R; Nesland JM
J Clin Pathol; 2003 May; 56(5):368-73. PubMed ID: 12719458
[TBL] [Abstract][Full Text] [Related]
19. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
[TBL] [Abstract][Full Text] [Related]
20. [Immunohistochemical investigation of steroid hormones (ER, PR) in breast cancer].
Mchedlishvili MIu; Gabunia UA; Makharoblidze ER; Burnadze KT; Piradashvili DZ
Georgian Med News; 2005 Feb; (119):65-7. PubMed ID: 15834186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
